{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:45:41Z","timestamp":1785527141400,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10549-026-07994-6","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:42:36Z","timestamp":1782132156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer"],"prefix":"10.1007","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9544-1193","authenticated-orcid":false,"given":"Yuhei","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2232-6315","authenticated-orcid":false,"given":"Mai","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-8575","authenticated-orcid":false,"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Natori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-5090","authenticated-orcid":false,"given":"Taro","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Kitadai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shosuke","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Maejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"7994_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/CAAC.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA et al (2024) Breast cancer statistics 2024. CA Cancer J Clin 74:477\u2013495. https:\/\/doi.org\/10.3322\/CAAC.21863","journal-title":"CA Cancer J Clin"},{"key":"7994_CR2","doi-asserted-by":"publisher","first-page":"103691","DOI":"10.1016\/J.ESMOOP.2024.103691","volume":"9","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, Punie K, Carey LA et al (2024) Real-world treatment patterns and outcomes in patients with HR+\/HER2- metastatic breast cancer treated with chemotherapy in the United States. ESMO Open 9:103691. https:\/\/doi.org\/10.1016\/J.ESMOOP.2024.103691","journal-title":"ESMO Open"},{"key":"7994_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMOA2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMOA2203690","journal-title":"N Engl J Med"},{"key":"7994_CR4","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R et al (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391:2110\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa2407086","journal-title":"N Engl J Med"},{"key":"7994_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000524227","volume":"89","author":"D Grassini","year":"2022","unstructured":"Grassini D, Cascardi E, Sarotto I et al (2022) Unusual patterns of HER2 expression in breast cancer: insights and perspectives. Pathobiology 89:278\u2013296. https:\/\/doi.org\/10.1159\/000524227","journal-title":"Pathobiology"},{"key":"7994_CR6","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105\u20132122. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"7994_CR7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/HIS.15273","volume":"85","author":"MA Hempenius","year":"2024","unstructured":"Hempenius MA, Eenkhoorn MA, H\u00f8eg H et al (2024) Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study. Histopathology 85:920\u2013928. https:\/\/doi.org\/10.1111\/HIS.15273","journal-title":"Histopathology"},{"key":"7994_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/PAI.0000000000000646","volume":"27","author":"E Lucas","year":"2019","unstructured":"Lucas E, Jabbar SB, Molberg K et al (2019) Comparison of Dako HercepTest and ventana PATHWAY anti-HER2 (4B5) tests and their correlation with fluorescent in situ hybridization in breast carcinoma. Appl Immunohistochem Mol Morphol 27:403\u2013409. https:\/\/doi.org\/10.1097\/PAI.0000000000000646","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"7994_CR9","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/J.ESMOOP.2023.101615","volume":"8","author":"G Viale","year":"2023","unstructured":"Viale G, Basik M, Niikura N et al (2023) Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO Open 8:101615. https:\/\/doi.org\/10.1016\/J.ESMOOP.2023.101615","journal-title":"ESMO Open"},{"key":"7994_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-40715-x","volume":"14","author":"L-J Dai","year":"2023","unstructured":"Dai L-J, Ma D, Xu Y-Z et al (2023) Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer. Nat Commun 14:1\u201313. https:\/\/doi.org\/10.1038\/s41467-023-40715-x","journal-title":"Nat Commun"},{"key":"7994_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/IJMS20030510","volume":"20","author":"G Lopez","year":"2019","unstructured":"Lopez G, Costanza J, Colleoni M et al (2019) Molecular insights into the classification of luminal breast cancers: the genomic heterogeneity of progesterone-negative tumors. Int J Mol Sci 20:510. https:\/\/doi.org\/10.3390\/IJMS20030510","journal-title":"Int J Mol Sci"},{"key":"7994_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/J.EJCA.2023.04.026","volume":"188","author":"T Geukens","year":"2023","unstructured":"Geukens T, De Schepper M, Richard F et al (2023) Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer. Eur J Cancer 188:152\u2013160. https:\/\/doi.org\/10.1016\/J.EJCA.2023.04.026","journal-title":"Eur J Cancer"},{"key":"7994_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/S10549-020-05935-5","volume":"185","author":"E Van Raemdonck","year":"2021","unstructured":"Van Raemdonck E, Floris G, Berteloot P et al (2021) Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. Breast Cancer Res Treat 185:183\u2013194. https:\/\/doi.org\/10.1007\/S10549-020-05935-5","journal-title":"Breast Cancer Res Treat"},{"key":"7994_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/CNCR.35101","volume":"130","author":"M Lin","year":"2024","unstructured":"Lin M, Luo T, Jin Y et al (2024) HER2-low heterogeneity between primary and paired recurrent\/metastatic breast cancer: implications in treatment and prognosis. Cancer 130:851\u2013862. https:\/\/doi.org\/10.1002\/CNCR.35101","journal-title":"Cancer"},{"key":"7994_CR15","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M et al (2023) Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol 41:3867\u20133872. https:\/\/doi.org\/10.1200\/JCO.22.02864","journal-title":"J Clin Oncol"},{"key":"7994_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/LIFE14010031","volume":"14","author":"X Ma","year":"2023","unstructured":"Ma X, Zhou L, Wu Q et al (2023) Loss of human epidermal receptor 2 expression in formalin-fixed paraffin-embedded breast cancer samples and the rescuing effect of enhanced antigen retrieval and signal amplification. Life (Basel) 14:31. https:\/\/doi.org\/10.3390\/LIFE14010031","journal-title":"Life (Basel)"},{"key":"7994_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1158\/1055-9965.667.13.4","volume":"13","author":"JH Fergenbaum","year":"2004","unstructured":"Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME (2004) Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 13:667\u2013672. https:\/\/doi.org\/10.1158\/1055-9965.667.13.4","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"7994_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/LABINVEST.2015.138","volume":"96","author":"SE Combs","year":"2016","unstructured":"Combs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL (2016) Loss of antigenicity with tissue age in breast cancer. Lab Invest 96:264\u2013269. https:\/\/doi.org\/10.1038\/LABINVEST.2015.138","journal-title":"Lab Invest"},{"key":"7994_CR19","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/APM.12884","volume":"126","author":"A Ehinger","year":"2018","unstructured":"Ehinger A, Bendahl P-O, Ryd\u00e9n L, Fern\u00f6 M, Alkner S (2018) Stability of oestrogen and progesterone receptor antigenicity in formalin-fixed paraffin-embedded breast cancer tissue over time. APMIS 126:746\u2013754. https:\/\/doi.org\/10.1111\/APM.12884","journal-title":"APMIS"},{"key":"7994_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1089\/BIO.2022.0090","volume":"21","author":"K Kim","year":"2023","unstructured":"Kim K, Ylaya K, Perry C et al (2023) Quality assessment of proteins and RNA following storage in archival formalin-fixed paraffin-embedded human breast cancer tissue microarray sections. Biopreserv Biobank 21:493\u2013503. https:\/\/doi.org\/10.1089\/BIO.2022.0090","journal-title":"Biopreserv Biobank"},{"key":"7994_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.21873\/ANTICANRES.18015","volume":"46","author":"S Sasada","year":"2026","unstructured":"Sasada S, Takaya M, Suzuki K et al (2026) Differences of HER2 status by HercepTest and PATHWAY 4B5 immunohistochemical assays in breast cancer. Anticancer Res 46:1123\u20131130. https:\/\/doi.org\/10.21873\/ANTICANRES.18015","journal-title":"Anticancer Res"},{"key":"7994_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/S10549-024-07532-2","volume":"210","author":"T Sakatani","year":"2025","unstructured":"Sakatani T, Tsuda H, Yoshida M et al (2025) Current status and challenges in HER2 IHC assessment: scoring survey results in Japan. Breast Cancer Res Treat 210:27\u201336. https:\/\/doi.org\/10.1007\/S10549-024-07532-2","journal-title":"Breast Cancer Res Treat"},{"key":"7994_CR23","doi-asserted-by":"publisher","first-page":"100925","DOI":"10.1016\/J.MODPAT.2025.100925","volume":"39","author":"EA Rakha","year":"2026","unstructured":"Rakha EA, Tan PH, Van Bockstal MR et al (2026) International expert consensus recommendations for HER2 reporting in breast cancer: focus on HER2-low and ultralow categories. Mod Pathol 39:100925. https:\/\/doi.org\/10.1016\/J.MODPAT.2025.100925","journal-title":"Mod Pathol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07994-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07994-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07994-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:09:13Z","timestamp":1785521353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07994-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7994"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07994-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of the National Cancer Center Hospital (IRB Number: 2014-092).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived due to the retrospective design of the study. Patient data were anonymized prior to analysis to ensure confidentiality.","order":2,"name":"Ethics","label":"Consent to participate and consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"59"}}